Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

The company has chosen to move ahead to Phase III trials with its 10mg dose after it saw a 1.74-point reduction in pain score ...

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. | Lexicon Pharmaceuticals ...

Sen. Mark Kelly champions the PAIN Act to improve seniors' access to non-opioid pain treatments under Medicare.

Ben Hargreaves finds that a new line of attack could be the development of more effective non-opioid painkillers, with one potential therapy moving closer to approval. The opioid epidemic in the ...

The hope is that a new generation of non-opioid analgesics will become available to treat both acute and chronic pain and have a reduced risk of addiction. In 2023, more than 100,000 lives were ...

Leaders with Project Opioid, a non-profit established after the opioid epidemic was declared a public health emergency in ...

Mexico has handled the cartels so poorly that it broke international law. It is obligated to prevent the harm cartels are ...

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look ...

Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization -- -- Adds novel, high-capacity, local ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...

The Food and Drug Administration (FDA) has granted Fast Track designation to LTG-001 for the treatment of acute pain. LTG-001, an oral Nav1.8 selective ...